Pharmaceutical company BioPharmX Corporation (NYSE American:BPMX) disclosed on Thursday its net loss of USD4.4m (USD0.02 per share) for the fiscal Q2 2019.
This is a decline in earnings when compared with a lower net loss of USD3.7m (USD0.05 per share) during the prior fiscal year's second quarter.
Revenues, net of USD24,000 were generated in fiscal Q2 2018, a growth over revenues, net USD17,000 in the prior fiscal year's second quarter.
Total operating expenses of USD4.3m were recorded in the prior fiscal year's second quarter.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva